Search Results

Reproductive and developmental toxicology data from trivalent influenza vaccines do not predict an increased risk of developmental abnormalities.

https://www.seqirus.ca/-/media/seqirus-canada/docs-en/flucelvax-product-monograph---english-2022.pdf

Seqirus Receives Health Canada Approval for Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People as Young as Six Months

https://www.seqirus.ca/news/seqirus-receives-health-canada-approval-for-expanded-age-indication-for-people-as-young-as-6-months

9.2 Drug Interactions Overview No interaction studies have been performed on interaction between influenza vaccines in general and other vaccines or medications.

https://www.seqirus.ca/-/media/seqirus-canada/docs-en/afluria-tetra--product-monograph-2021-2022.pdf

Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.

https://www.seqirus.ca/

NEJM study indicates that the seasonal influenza vaccine was effective and produced a sufficient immune response against influenza in children and adolescents ≥2 to <18 years of age

https://www.seqirus.ca/news/nejm-study-cell-based-quadrivalent-influenza-vaccine-efficacy-in-children

Seqirus is a global influenza vaccine company developing innovative solutions to ensure epidemic and pandemic preparedness throughout the world.

https://www.seqirus.ca/our-company

As is with other influenza vaccines, children who have received the appropriate course of FLUAD® Pediatric or another seasonal influenza vaccine are considered to be primed.

https://www.seqirus.ca/-/media/seqirus-canada/docs-en/2021-2022-fluad-product-monograph.pdf

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.ca/news

Reproductive and developmental toxicology data from trivalent influenza vaccines do not predict an increased risk of developmental abnormalities.

https://www.seqirus.ca/-/media/seqirus-canada/docs-en/flucelvax-quad-ca-pm-2-approved-8mar2021.pdf

Seqirus Announces Health Canada Approval of Expanded Age Indication

https://www.seqirus.ca/news/seqirus-announces-health-canada-approval-of-expanded-age-indication